80 results about "Linear epitope" patented technology

The invention belongs to the technical field of biological engineering and in particular is a heat-induced fusion expression recombinant plasmid of truncated GST protein and a process for preparation. The invention selects utility truncated GST188 protein which is composed of 188aa as a carrier, a pXXGST-1 recombinant plasmid which expresses short peptide fusion protein in an escherichia coli heat-induced expression system and a heat-induced type pXXGST-2 recombinant plasmid which is used to express comparison to realize the aim of synthesizing short peptide creatures, which is especially provided for scanning, drawing, positioning antigen linear epitopes and identifying epitope motif. Experiments of the invention prove the adaptability and the applicability of the GST188 core protein which is used as the short peptide creatures expression vector, in antigen epitope scanning identification, and in particular when anti- recombinant target protein antiserum is used to indentify the epitope motif.

The invention belongs to the technical field of biomedicine and biological detection, in particular to two linear epitope minimal motif peptides capable of being identified by human zona pellucida protein-4 (ZP4) monoclonal antibodies MA-1662 and MA-1671 on human ZP4 and extended eight peptides and application thereof. The invention provides two candidate epitopes which can be used for developing human immune birth control recombinant multi-epitope vaccines, and the amino acid sequences of the candidate epitopes are shown as SEQ ID No. 1 and marked as huZP4147-151 or shown as SEQ ID No.2 and marked as huZP4256-260; and the invention also provides candidate epitopes which can be used for developing novel high-specificity high-sensitivity recombinant multi-epitope detection antigens for diagnosing serum ZP antibodies of ZP autoimmune infertile women, and the amino acid sequences of the candidate epitopes are shown as SEQ ID No.3-SEQ ID No.6.

The invention discloses antiviral serotype shared monoclonal antibody of foot-and-mouth disease and a distinguished epitope thereof and the application, belonging to the prevention and control field of foot-and-mouth disease. The invention obtains two hybridoma cell lines which can secrete antiviral serotype shared monoclonal antibody of foot-and-mouth disease (microorganism maintenance numbers thereof are CGMCC No. 3103 and CGMCC No. 3104 respectively), and monoclonal antibodies 4B2 and 3D9 which are secreted by the hybridoma cell lines. ELISA and indirect immunofluorescence assay show that the two hybridoma cell lines both belong to FMDV shared monoclonal antibodies; wherein the 4B2 distinguishes one linear epitope of FMDV, and the 3D9 distinguishes one conformation epitope of FMDV. The4B2 and 3D9 are respectively used as a capture antibody and a detection antibody, a method for capturing ELISA by an antigen is adopted, specificity detection of FMDV can be carried out; the detectionmethod has the characteristics of high sensibility, strong specificity and good repeatability.

The invention is applicable to the technical field of biology, and provides a B cell linear epitope of a novel coronavirus S protein, an antibody, an identification method and an application, and theamino acid sequence of the B cell linear epitope of the S protein is shown as SEQ ID NO.104 or SEQ ID NO.82. The invention provides a brand-new B cell linear epitope of the novel coronavirus S protein, which can be used for detecting a specific antibody in blood of a COVID-19 patient, and can also be used for being inoculated into healthy people to induce generation of the specific antibody, so that an important antigen target is provided for design of an SARS-CoV-2 vaccine, research and development of the monoclonal antibody and research and development of an antibody detection kit.

The invention belongs to the technical field of biological medicine and biological detection and particularly relates to an epitope minimum motif peptide of P1, VP2 and VP4 structural proteins in a type O foot and mouth disease virus (FMDV) strain (O/BY/CHA/2010) and application of the epitope. Five linear epitope minimum motif peptides provided by the invention can be used as candidate epitope peptides for research and development of a novel recombinant multi-epitope peptide vaccine against type O FMDV and have amino acid sequences as shown in SEQ. ID NO.1-SEQ. ID NO.5. The invention also provides a candidate epitope for research of a detection antigen of a high-specificity and high-sensitivity recombinant multi-epitope peptide for diagnosing prevalence of the FMDV and the candidate epitope has amino acid sequences as shown in the SEQ. ID NO.6-SEQ. ID NO.10.

The invention belongs to the technical field of biomedicine and bioinstrumentation, in particular to an epitope (Bcellepitope) minimum motif peptide of human papilloma virus (HPV) type 58 L1 structural protein and application thereof. The invention provides 16 amino acid sequences containing minimum motif peptide (including 8 peptide sequence capable of cutting off expression of carrier protein such as GST188), and the amino acid sequences can be taken as antigen for independently or combinedly specific detection of blood serum of HPV type 58 virus infection patient and can be used for developing preventive HPV type 58 multi-epitope peptide vaccine capable of simultaneously inducing humoral immunity. The amino acid sequences of HPV type 58 L1 epitope minimum motif peptide and short peptide are shown as SEQIDNo.1-SEQIDNo.32.

The invention relates to linear epitope minimum motif peptides of PPRV (peste des petits ruminants virus) N (nucleocapsid) protein and an application of the linear epitope minimum motif peptides. Aiming at a Tibetan isolate PPRV N protein with high immunogenicity, an improved short peptide biosynthesis method and an anti-recombinant protein polyclonal antibody are adopted, a complete-sequence fine linear B cell epitope map is provided and comprises 20 minimum epitope motif contained epitope peptides which can be used for detecting the infection serum of the PPRV independently or in a combined manner. And further, an epitope map with broad spectrum applicable to various PPRVs is provided.

The invention provides a 2019-nCoV N protein linear epitope peptide, a monoclonal antibody and application. The amino acid sequence of the 2019-nCoV N protein linear epitope peptide is as shown in any one of SEQ ID NO.1-5. The polypeptide carrier protein containing the linear epitope peptide is coupled with an immunized mouse to prepare a plurality of hybridoma cells which secrete monoclonal antibodies which can specifically recognize2019-nCoV N protein and have biological activity.

The invention discloses a method for preparing a brain natriuretic peptide precursor N-terminal (NT-proBNP) linear epitope by displaying an antigenic epitope through human-derived skeleton protein Fn3 (human fibronectin 3). According to the method, through genetic recombination, an antigenic epitope nucleotide sequence capable of being combined with an anti-brain-natriuretic-peptide precursor antigen is used for replacing a nucleotide sequence in an encoding FG region of the skeleton protein Fn3, a fusion gene of the skeleton protein Fn3 and the NT-proBNP linear epitope is formed, an escherichia coli expression system is used for efficient expression, and fusion protein with the skeleton protein Fn3 and the NT-proBNP linear epitope fused is prepared. The method has the advantages that the fusion protein with antigenicity equivalent to that of a brain natriuretic peptide precursor can be easily, quickly and efficiently prepared, and a foundation is laid for efficiently preparing a standard substance with brain natriuretic peptide precursor antigenicity at low cost.

The present invention relates to anti-human respiratory syncytial virus N protein antibodies and immunochromatographic kit for detection of human respiratory syncytial virus by using the same. The anti-human respiratory syncytial virus N protein antibodies separately recognize two linear epitopes consisting of No.21-34 amino acids and No.226-239 of human respiratory syncytial virus N protein; the human respiratory syncytial virus N protein has sequence number of AAB59852.1 in GenBank; amino acid sequence of sites No.21-34 and No.226-239 of the human respiratory syncytial virus N protein are respectively SKYTIQRSTGDSID and FGIAQSSTRGGSRV. The two kinds of rabbit anti-human respiratory syncytial virus N protein antibodies have the characteristics of good specificity, high purity, high titer and low preparation cost.

The invention relates to a liposome influenza virus antigen vaccine and a preparing method thereof. The liposome influenza virus antigen vaccine is prepared with a film evaporation method. The preparing method includes the steps of preparing an influenza virus antigen vaccine stock solution, preparing empty liposome, synthesizing liposome and the like. Compared with a linear epitope vaccine, the liposome influenza virus antigen vaccine prepared with the preparing method of the liposome influenza virus antigen vaccine has the advantages that multiple or multiple kinds of antigens can be carried at the same time, various cellular immune responses can be induced, and high immune responses can be caused; in addition, the liposome influenza virus antigen vaccine is stable in performance and long in storage life, and meanwhile the use immunogen dosage can be reduced.

The invention provides a scylla paramamosain sensitizing protein Scy p 1 derivative and an application thereof. The amino acid sequence of the derivative is shown as SEQ ID NO:1. According to the scylla paramamosain sensitizing protein Scy p 1 derivative, an N terminal, a C terminal and two key linear epitope regions of a wild type Scy p 1 amino acid sequence are deleted. Amplifying is carried outthrough an overlap extension PCR technology to obtain an Scy p 1 derivative gene sequence; connecting and transforming into a BL21 host cell are carried out, and inducible expression is carried out;the expressed derivative is purified by a Ni column, and the influence of Scy p 1 on mast cell degranulation before and after transformation is analyzed. Compared with wild-type Scy p 1, the Scy p 1 derivative can significantly reduce release of beta-aminohexosidase in LAD2 cells, is expected to be used for immunotherapy or immunological prevention, and reduces side effects in immunotherapy so asto improve the safety index of treatment.

The present invention discloses an avian influenza virus NS1 protein B cell epitope polypeptide and applications thereof. According to the present invention, prokaryotic expressed and purified NS1 recombinant protein is adopted to immunize BALB/c mice, a lymphocyte hybridoma technology is adopted to prepare hybridoma cells, and indirect ELISA is adopted to screen to obtain two strains of hybridoma cells capable of stably secreting anti-NS1 protein MAbs, wherein Western blot identification results show that the two strains of the MAbs can identify NS1 recombinant protein; and an oligopeptide WNLNTVRVS corresponding to D9 and obtained by using a phage display technology is basically matched with aa 182-190 of NS1 protein, such that the result prompted that 182WNDNTVRVS190 is alinear epitope of NS1 protein. The present invention further relates to applications of the antigen epitope polypeptide in preparation of drugs for diagnosis or detection of avian influenza virus infections so as to provide a theoretical basis for further establishment of an efficient avian influenza detection method.

The invention belongs to the technical field of immunity, and particularly discloses a linear epitope, with following amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and/or SEQ ID NO: 3, of a novelcoronavirus RBD specific monoclonal antibody. The invention also discloses application of the linear epitope of the novel coronavirus RBD specific monoclonal antibody. The linear epitope of the novelcoronavirus RBD specific monoclonal antibody has important significance in research and development of vaccines against the COVID-19 and research, development, diagnosis, prevention and treatment ofsmall molecular drugs.

The invention discloses a multi sub-gene resistant type HCV (Hepatitis C Virus) antibody gene R3-19, wherein the heavy chain amino acid sequence thereof is shown by SEQ ID NO.38, and the light chain amino acid sequence is shown by SEQ ID NO.39, the antibody gene is obtained by vanning in an independently-constructed anti-HCV scFv antibody library through E2 region aa412-423 linear epitope (an HCV CD81 receptor binding epitope) synthetic peptide which is highly conservative in various subtype HCVs; the antibody library is formed by 39 parts of anti-HCV antibody positive peripheral blood samples of Chinese patients, the HCVs infected by the patients cover the main HCV popular subtypes in China, therefore, the R3-19 is an anti-HCV antibody which is typical in China and has wide binding characteristic, and has excellent application value in the fields of HCV diagnosis, HCV treatment, vaccine research and development and the like in China.

The invention relates to an avian influenza virus NP proteantigen epitope peptide and a colloidal gold test paper box thereof. The invention provides an avian influenza H9N2 subtype virus NP protein linear epitope peptide, and the antigen epitope peptide has the amino acid sequence of SEQ ID NO: 1. The antigen epitope peptide provided by the invention is used for preparing a product for detecting avian influenza virus. The avian influenza virus NP protein B cellular antigen epitope peptide is identified for providing a ground for further establishing a method of efficiently detecting avian influenza, and also lays a foundation for studying the structure and function of NP protein.

The invention relates to a predication and verification method of a serum amyloid protein A (SAA) antigen epitope and a preparation method of a monoclonal antibody. The predication and verification method comprises the following steps: predicating surface accessibility, an flexibility sequence region, a beta turn, antigenicity, hydrophilicity, a linear epitope and a long-fragment epitope of a serum amyloid protein A antigen to obtain a plurality of epitope sequences respectively; removing repeated epitopes in the plurality of epitope sequences and other sequences contained in other relativelylong epitopes to obtain a plurality of non-redundant predication epitopes; and verifying whether the plurality of non-redundant predication epitopes are identification epitopes of the antibody or notby adopting ELISA (Enzyme Linked Immunosorbent Assay). According to the invention, the problem that the predication accuracy of a single method is low is overcome; through experimental verification, the problem that the SAA antigen epitope is unknown is solved; and the monoclonal antibody is prepared by applying synthesized antigen epitope polypeptide, so that the problem that SAA is difficult topurify and obtain is overcome and the cost is reduced by one time or more.

The invention provides a method for assisting in identifying linear epitope of a plant food allergen. The method comprises the following steps of taking a product of a plant food protein which is subjected to simulating gastrointestinal digestion as a sample, and carrying out high-performance liquid chromatography; carrying out mass spectrum detection on the separated sample to obtain mass spectrum information of an anti-digestion peptide segment; and next, performing comparison and analysis with an amino acid full sequence of the plant food allergen to obtain the peptide segment matched withthe plant food allergen. The peptide segment obtained by the method of the invention has correlation, or coverage or cross with the linear epitope of the allergen. Therefore, the range for identifyingthe linear epitope can be reduced and the identifying can be more targeted, and compared with the existing method for identifying the linear epitope, the assisting method reduces the workload of thewhole identification process, and the identification result is more accurate.

The invention provides a cyclic citrullinated peptide, an antigen containing the cyclic citrullinated peptide, a reagent containing the cyclic citrullinated peptide, a kit containing the cyclic citrullinated peptide and application. In order to solve the problem that in the prior art, a disulfide bond at a cyclic structure of the cyclic citrullinated peptide is easy to break, so that an amino acid residue linear epitope outside a citrulline antibody recognition key region is exposed and recognized by other antibodies, and false positive occurs, the cyclic citrullinated peptide provided by the invention has the advantages that a peptide fragment at one end of a citrulline residue and a peptide fragment at the other end of the citrulline residue are connected into a ring through a carbon-sulfur bond. Compared with a disulfide bond formed between two cysteines C in natural cyclic citrulline, the carbon-sulfur bond is shorter in bond length, larger in bond energy and not easy to break, the probability that the amino acid residue linear epitope outside the citrulline antibody recognition key region is recognized by the other antibodies is lowered, false positive is lowered, and the clinical detection specificity of a cyclic citrullinated peptide antibody in RA disease diagnosis is improved.

A method for quantitative detection of allergen beta-lactoglobulin and sensitization residues thereof based on an IgE linear epitope polyclonal antibody comprises the steps of preparing beta-lactoglobulin IgE epitope concatemer protein through the recombinant expression technology, preparing a corresponding polyclonal antibody through the conventional technology with the concatemer protein and beta-lactoglobulin serving as the antigens, and preparing a specific antibody through affinity purification.Sandwich elisa is established with the beta-lactoglobulin polyclonal antibody as a capture antibody and the biotinylation concatemer polyclonal antibody as a detection antibody, the light absorption value is detected through a enzyme-linked immunometric meter, and the quantitative detection of beta-lactoglobulin and the sensitization residues thereof on food is achieved by establishing standard curves.The established method has the advantages of being simple in operation, high in sensitivity, good in specificity and the like, an effective method is provided for high-throughput analysis and detection of multiple relevant allergens and sensitization residues thereof in food, and the method has wide popularization and application prospects.

The invention discloses a method for preparing a pro-brain natriuretic peptide epitope by virtue of Bacillus brevis (B.brevis). According to the method, the nucleotide sequence of N-terminal pro-brain natriuretic peptide linear epitope (NT-BNP<12-21>) capable of being bound with a pro-brain natriuretic peptide antibody is replaced by the nucleotide sequence of a coding region FG of human fibronectin 3 (Fn3) to form a fusion gene of Fn3 and NT-BNP<12-21> linear epitope, the fusion gene is inserted into the downstream of a signal peptide P2 of shuttle plasmid pNCMO2 to construct recombinant plasmid pNCMO2-Fn3-NT-BNP<12-21>, and the recombinant plasmid is enabled to express the secretory fusion protein formed through fusion of the skeleton protein Fn3 and NT-BNP<12-21> linear epitope with high efficiency in B.brevis. The method disclosed by the invention is capable of simply and rapidly preparing the secretory fusion protein having the antigenicity equivalent to that of pro-brain natriuretic peptide with high efficiency and low cost.